Subtitle: Market Intelligence, Clinical Progress, Resistance Mechanisms, and High-Purity Reagents for Prostate Cancer & Beyond.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | CYP17A1 Full-Length Recombinant Protein HEK293 Expressed, Sequence Verified, Theoretical MW ~57 kDa, High Purity (>95%), Endotoxin <1EU/μg. |
View CYP17A1 Products |
| Resistance Panel | CYP17A1 Mutant Proteins (F98W, T96L, A105V) Abiraterone-resistant variants for mechanism studies, Endotoxin <1EU/μg |
View CYP17A1 Products |
| Gene Delivery | CYP17A1 Premade Lentivirus Full-length ORF for stable cell line construction in steroidogenic cell models |
View CYP17A1 Products |
| Benchmark Ab | Anti-CYP17A1 (Research Grade) Rabbit monoclonal for Western/ICW validation |
View CYP17A1 Products |
| Validator | CYP17A1 siRNA Set Gene-specific knockdown for target validation in LNCaP/HEK293 cells |
View CYP17A1 Products |
| Related Target (Selectivity) | CYP11B1 (11β-Hydroxylase) Critical counter-screen to avoid cortisol synthesis inhibition |
View CYP11B1 Products |
| Related Target (Selectivity) | CYP11B2 (Aldosterone Synthase) Off-target liability assessment for cardiovascular safety |
View CYP11B2 Products |
| Related Target (Pathway) | AR (Androgen Receptor) Downstream signaling node for combination therapy studies |
View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Abiraterone Resistance Profiling (F98W/T96L) | Site-directed mutagenesis panel with sequence-verified resistance mutants, >95% purity |
| CYP11B1/CYP11B2 Selectivity Screening | Ortholog protein panel (Human/Mouse/Cyno) with identical expression systems for direct comparison |
| Lyase vs Hydroxylase Activity Discrimination | Functional enzyme formats with heme cofactor intact for bifurcated assay readouts |
| Cellular Androgen Production Assay | Lentivirus-mediated stable expression in HEK293 or steroidogenic background lines |
Live CYP17A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CYP17A1 inhibitor landscape is transitioning from first-generation pan-inhibitors (abiraterone) to next-generation precision therapeutics. While abiraterone acetate established proof-of-concept for hormonal blockade in metastatic castration-resistant prostate cancer (mCRPC), the field is rapidly evolving toward selective 17,20-lyase inhibitors and bifunctional degraders (PROTACs) to overcome resistance mechanisms and mineralocorticoid side effects. As first-generation therapies like abiraterone acetate face generic competition and resistance in mCRPC, the next wave of R&D targets tissue-specific enzyme conformations, dual AR/CYP17 inhibition, and mutant-specific profiles for improved therapeutic indices.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Irreversible Inhibitors (Abiraterone-like) | Janssen (J&J), Tokai Pharma, Sevion, Generics | mCRPC, High-risk CSPC | Resistance Mutant Panel (F98W, T96L) & Selectivity Assay (CYP17A1 vs CYP11B1/2) |
| Selective 17,20-Lyase Inhibitors | Forma Therapeutics, Takeda (Orteronel legacy) | Prostate Cancer, CAH | Bifurcated Activity Assay (Lyase vs Hydroxylase) with WT protein |
| CYP17 PROTACs | Arvinas, Emerging Biotechs | CRPC (Abiraterone-resistant) | Cell-based Lentivirus Systems for degradation kinetic studies |
| Dual CYP17/CYP11B Inhibitors | OntoChem, University labs | Cushing's Syndrome, CRPC | Dual Ortholog Panel (CYP17A1 + CYP11B1/2) for selectivity indexing |
| Hormonal Combinations | AstraZeneca, Pfizer | Breast Cancer (AR+) | AR Pathway Co-expression assays |